Reactivating NK Cells in Treating Refractory Head and Neck Cancer
Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This study aims to determine the safety and efficacy of expanded activated autologous NK
cells administered after cetuximab in patients with EGFR-positive nasopharyngeal carcinoma or
head and neck squamous cell carcinoma.